deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT03627767

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS

Sponsor: Pfizer

Conditions Dermatitis Dermatitis, Atopic Eczema Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic
Interventions PF-04965842 100 mg PF-04965842 200 mg Placebo
Updated 34 times since 2018 Last updated: Sep 17, 2021 Started: Jun 11, 2018 Primary completion: Sep 2, 2020 Completion: Oct 7, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03627767, this PHASE3 trial focuses on Dermatitis and Dermatitis, Atopic and remains completed. Sponsored by Pfizer, it has been updated 34 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 8 months · monthly snapshot

Change History

34 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 29 earlier versions

  1. Oct 2021 — Dec 2021 [monthly]

    Completed PHASE3

  2. Feb 2021 — Oct 2021 [monthly]

    Completed PHASE3

  3. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE3

  4. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  10. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  11. Mar 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

  12. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  13. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  14. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  15. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  16. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  17. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  18. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  19. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  20. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  21. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  22. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  23. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  24. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  25. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  26. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  27. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  28. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  29. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico , Ajax, Canada , Alicante, Spain , Atlanta, United States , Badalona, Spain , Banská Bystrica, Slovakia , Barcelona, Spain , Barrie, Canada , Baton Rouge, United States , Bay Pines, United States and 161 more locations